TL;DR
The economic engines of major US managed care organizations are facing a dual challenge as federal regulators dismantle opaque pharmacy benefit manager (PBM) profit centers and hospital networks push back against Medicare Advantage denials. In response, payers are executing defensive pivots, shifting commercial clients to transparent flat-fee pricing and betting on complex federal risk-adjustment pools to sustain profitability. This transition marks a critical shift away from hidden spread pricing and toward highly regulated administrative and risk-transfer margins.
The Regulatory Squeeze on Vertically Integrated PBMs
The highly lucrative, opaque pricing mechanisms of vertically integrated pharmacy benefit managers are facing an unprecedented operational and legal dismantling.
The Federal Trade Commission (FTC) secured a sweeping settlement with Express Scripts (ESI) as detailed by the FTC.
"The FTC’s settlement with ESI will end its business practices that have kept drug prices high, ultimately providing meaningful financial relief to American patients who depend on ESI to access life-sustaining prescription drugs as well as community pharmacies who will see new revenues each year and relief from being squeezed." — Regulatory and Legislative Crackdown on PBMs and Vertical Integration
By forcing the reshoring of offshore group purchasing organizations like Ascent and prohibiting the preferencing of high-list-price drugs, regulators are systematically closing the rebate trap that historically inflated pharmacy benefit margins. This clampdown, combined with state-level ownership limits like Tennessee's FAIR Rx Act, threatens to structurally untangle the vertical integration that has defined modern managed care profitability [cigna-evernorth-pivot-commercial-focus].
What to watch: Watch whether the federal Patients Before Monopolies Act progresses past committee stages to force outright pharmacy divestitures.
Government-Sponsored Program Friction and Risk-Pool Arbitrage
Insurers are facing intense operational headwinds in government-sponsored programs, driving a strategic divergence between contracting Medicare Advantage footprints and betting heavily on complex Affordable Care Act marketplace risk pools.
Centene's management highlighted this dependency during their initial quarterly earnings call, as transcribed by Fortune.
"The June Wakely data… will be key." — Centene: Marketplace Risk Adjustment and the June Wakely Consulting Catalyst
While UnitedHealthcare faces severe provider friction—culminating in Fairview Health Services deciding to drop its Medicare Advantage plans [unitedhealth-optum-vertical-integration-medicare-advantage]—Centene is taking a calculated gamble on ACA risk transfers. By absorbing sicker, higher-acuity members, Centene expects to trigger massive federal risk-adjustment receivables that could recover its targeted Marketplace margins.
What to watch: Watch whether the release of the June Wakely Consulting Group data confirms the risk-score differentials needed to unlock Centene's margin targets.
The Defensive Transition to Transparent Administrative Fees
In response to mounting legislative and direct-to-consumer threats, dominant pharmacy benefit managers are aggressively transitioning clients to flat-fee administrative frameworks to preserve their commercial volume.
According to benefits attorney John Barlament, speaking for the IFEBP, initiatives like TrumpRx.gov threaten to disintermediate traditional payer stacks.
"The potential to lose important PBM prescription drug data by encouraging plan enrollees to use the TrumpRx process to obtain prescription drugs." — Regulatory and Legislative Crackdown on PBMs and Vertical Integration
To defend against this disintermediation and state-level bans on spread pricing, UnitedHealth’s Optum Rx has introduced a transparent pharmacy care framework [unitedhealth-optum-vertical-integration-medicare-advantage]. This shift swaps volatile, opaque rebate retention for predictable flat fees, attempting to lock in commercial employer relationships before legislative mandates force their hand [cigna-evernorth-pivot-commercial-focus
].
What to watch: Watch whether federal courts rule in favor of Optum Rx's ERISA preemption arguments to block state-level pharmacy restrictions.
What surprised us
- Hospital networks are starting to walk away from Medicare Advantage altogether. While insurers often rely on clinical denials to manage their medical loss ratios, the backlash is reaching a tipping point. Fairview Health Services' decision to discontinue accepting UnitedHealthcare Medicare Advantage plans
by 2027 shows that clinical partners are willing to drop major payers entirely rather than absorb the administrative costs of high denial rates and payment delays.
- Cigna's de-risked commercial strategy has concentrated its policy risk in a highly targeted basket. By divesting its volatile Medicare Advantage business to focus on Evernorth and commercial employers [cigna-evernorth-pivot-commercial-focus
], Cigna successfully avoided the government-sponsored "benefit cliff." However, this pivot has left the company uniquely exposed to the FTC's aggressive dismantling of Express Scripts' core rebate and GPO structures.
- Sicker members are the key to Centene's margin recovery. While conventional underwriting dictates avoiding high-acuity populations, Centene is leveraging its high-acuity Silver-tier membership [centene-marketplace-risk-adjustment-wakely-catalyst
] to trigger massive federal risk-adjustment receivables. In government-sponsored marketplaces, managing sicker risk pools can actually be more lucrative than enrolling healthy ones, provided the actuarial data supports the transfer.
Open threads worth a vote
- Federal Court Ruling on Optum Rx California S.B. 41 Lawsuit: Vote to prioritize our tracking of the federal court's decision on ERISA preemption, which could set a major precedent for state-level PBM restrictions.
- Congress Progress on Patients Before Monopolies Act (PBM Act): Help us steer our coverage of federal legislative efforts to force structural divestitures of pharmacies from PBMs and insurers.